Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer

Biological & Pharmaceutical Bulletin
Hai-Bo XiYu Li

Abstract

Dendritic cell (DC)-based vaccines are a promising therapeutic modality for cancer. Results from recent trials and approval of the first DC vaccine by the U.S. Food and Drugs Administration for prostate cancer have paved the way for DC-based vaccines. A total of 21 hormone refractory prostate cancer (HRPC) patients with a life expectancy >3 months were randomised into two groups. DC loaded with recombinant Prostate Specific Membrane Antigen (rPSMA) and recombinant Survivin (rSurvivin) peptides was administered as an subcutaneous (s.c.) injection (5×10(6) cells). Docetaxel (75 mg/m(2) intravenous (i.v.)) and prednisone (5 mg, bis in die (b.i.d.)) served as control. Clinical and immunological responses were evaluated. Primary endpoints were safety and feasibility; secondary endpoint was overall survival. Responses were evaluated on day 15, day 30, day 60, and day 90. DC vaccination was well tolerated with no signs of grade 2 toxicity. DC vaccination induced delayed-type hypersensitivity reactivity and an immune response in all patients. Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumours (RECIST) was 72.7% (8/11) versus 45.4 (5/11) in the docetaxel arm and immune related response criteria (irRC) was 54....Continue Reading

References

Jul 1, 1994·The Journal of Experimental Medicine·N RomaniG Schuler
Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Feb 12, 1998·The Journal of Experimental Medicine·G Schuler, R M Steinman
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Aug 13, 1998·Nature Medicine·F KernH D Volk
Jul 1, 1999·The Prostate·B A TjoaG P Murphy
Aug 7, 1999·The New England Journal of Medicine·H S SwanaD C Altieri
Dec 14, 1999·The Journal of Investigative Dermatology·D GrossmanD C Altieri
Jul 4, 2001·Nature Medicine·F O NestleD Hart
Jun 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoni RibasJames S Economou
Jan 9, 2004·International Journal of Cancer. Journal International Du Cancer·Sine RekerMads Hald Andersen
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Apr 14, 2006·Cancer Immunology, Immunotherapy : CII·Ying Waeckerle-MenSilke Gillessen
Sep 16, 2006·International Journal of Cancer. Journal International Du Cancer·Anna-K Thomas-KaskelHendrik Veelken
Mar 19, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christian DoehnDieter Jocham
May 14, 2008·Reviews on Recent Clinical Trials·William C OlsonAyyappan K Rajasekaran
Jun 30, 2009·Cancer Treatment Reviews·Bríd M RyanMichael J Duffy
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Jan 9, 2013·Human Vaccines & Immunotherapeutics·Kuang YoulinWeng Xiaodong
Aug 10, 2013·Journal of Visualized Experiments : JoVE·Rachel Lubong SabadoNina Bhardwaj

❮ Previous
Next ❯

Citations

Jul 28, 2015·The Journal of Clinical Investigation·Cornelis J M MeliefSjoerd H van der Burg
Nov 13, 2019·Nature Reviews. Clinical Oncology·Martin J ConnorHashim U Ahmed
Apr 9, 2017·Journal of Hematology & Oncology·Shikhar MehrotraDavid J Cole
Dec 13, 2017·Expert Opinion on Biological Therapy·John C Henegan, Guru Sonpavde
May 30, 2020·International Journal of Cancer. Journal International Du Cancer·Vilde D HaakensenÅslaug Helland
Aug 16, 2017·Oncoimmunology·Abhishek D GargLorenzo Galluzzi
Dec 15, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lea LowenfeldBrian J Czerniecki
Apr 16, 2021·Frontiers in Immunology·Sarah I M SutherlandGeorgina J Clark
Jun 3, 2021·International Journal of Molecular Sciences·Nataša TešićUrban Švajger
Jul 3, 2021·Vaccines·Brigida Anna MaioranoEvaristo Maiello

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.